Our data suggest evodiamine improves glucose tolerance and prevents progress of insulin resistance associated with obese/diabetic states, at least in part, through AMPK activation followed by inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes. The gene discussed is IRS1; the disease is Insulin resistance.